Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies

被引：0
|
作者：
Calisti, Fabrizio [1 ]
Tocco, Michael [2 ,3 ]
Mao, Yongcai [2 ,3 ]
Pikalov, Andrei [2 ,3 ]
Goldman, Robert [2 ,3 ]
机构：
[1] Angelini Pharma SpA, Angelini RR&D Regulatory Res Dev, Viale Amelia 70, I-00181 Rome, Italy
[2] Sunov Pharmaceut Inc, Teaneck, NJ USA
[3] Sunov Pharmaceut Inc, Marlborough, MA USA
来源：
CNS SPECTRUMS | 2023年 / 28卷 / 02期
关键词：
D O I：
10.1017/S1092852923001876
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：248 / 249
页数：2
相关论文
共 50 条
  • [1] Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies
    Calisti, Fabrizio
    Tocco, Michael
    Mao, Yongcai
    Goldman, Robert
    ANNALS OF GENERAL PSYCHIATRY, 2024, 23 (01)
  • [2] Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naive versus previously treated adolescents with Schizophrenia: A post-hoc analysis
    Correll, Christoph U.
    Tocco, Michael
    Pikalov, Andrei
    Hsu, Jay
    Goldman, Robert
    SCHIZOPHRENIA RESEARCH, 2022, 240 : 205 - 213
  • [3] Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study
    Forester, Brent P.
    Sajatovic, Martha
    Tsai, Joyce
    Pikalov, Andrei
    Cucchiaro, Josephine
    Loebel, Antony
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2018, 26 (02): : 150 - 159
  • [4] LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN SCHIZOPHRENIA: RESULTS OF A 22 MONTH, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Cucchiaro, J.
    Silva, R.
    Hsu, J.
    Pikalov, A.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [5] Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study
    Correll, Christoph U.
    Cucchiaro, Josephine
    Silva, Robert
    Hsu, Jay
    Pikalov, Andrei
    Loebel, Antony
    CNS SPECTRUMS, 2016, 21 (05) : 393 - 402
  • [6] LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN SCHIZOPHRENIA: RESULTS OF A 22 MONTH, OPEN-LABEL EXTENSION STUDY
    Pikalov, Andrei
    Correll, Christoph
    Cucchiaro, Josephine
    Silva, Robert
    Hsu, Jay
    Loebel, Antony
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S178 - S178
  • [7] Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study
    Patel, Preeya J.
    Weidenfeller, Christian
    Jones, Andrew P.
    Nilsson, Jens
    Hsu, Jay
    NEUROLOGY AND THERAPY, 2021, 10 (01) : 121 - 147
  • [8] Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study
    Preeya J. Patel
    Christian Weidenfeller
    Andrew P. Jones
    Jens Nilsson
    Jay Hsu
    Neurology and Therapy, 2021, 10 : 121 - 147
  • [9] Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study
    Citrome, Leslie
    Cucchiaro, Josephine
    Sarma, Kaushik
    Phillips, Debra
    Silva, Robert
    Tsuchiya, Satoru
    Loebel, Antony
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2012, 27 (03) : 165 - 176
  • [10] Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies
    Costamagna, Isabella
    Calisti, Fabrizio
    Cattaneo, Agnese
    Hsu, Jay
    Tocco, Michael
    Pikalov, Andrei
    Goldman, Robert
    EUROPEAN PSYCHIATRY, 2021, 64 (01)
12345